{"downloaded": true, "htmlmade": false, "full": {"id": "29410180", "source": "MED", "pmid": "29410180", "pmcid": "PMC6091693", "fullTextIdList": {"fullTextId": "PMC6091693"}, "doi": "10.1016/j.bbmt.2018.01.039", "title": "Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.", "authorString": "Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF.", "authorList": {"author": [{"fullName": "Micallef IN", "firstName": "Ivana N", "lastName": "Micallef", "initials": "IN", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, Minnesota."}}}, {"fullName": "Stiff PJ", "firstName": "Patrick J", "lastName": "Stiff", "initials": "PJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology/Oncology, Loyola University, Chicago, Illinois."}}}, {"fullName": "Nademanee AP", "firstName": "Auayporn P", "lastName": "Nademanee", "initials": "AP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "City of Hope Comprehensive Cancer Center, Duarte, California."}}}, {"fullName": "Maziarz RT", "firstName": "Richard T", "lastName": "Maziarz", "initials": "RT", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}}}, {"fullName": "Horwitz ME", "firstName": "Mitchell E", "lastName": "Horwitz", "initials": "ME", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina."}}}, {"fullName": "Stadtmauer EA", "firstName": "Edward A", "lastName": "Stadtmauer", "initials": "EA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania."}}}, {"fullName": "Kaufman JL", "firstName": "Jonathan L", "lastName": "Kaufman", "initials": "JL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia."}}}, {"fullName": "McCarty JM", "firstName": "John M", "lastName": "McCarty", "initials": "JM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia."}}}, {"fullName": "Vargo R", "firstName": "Rita", "lastName": "Vargo", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sanofi, Cambridge, Massachusetts."}}}, {"fullName": "Cheverton PD", "firstName": "Peter D", "lastName": "Cheverton", "initials": "PD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sanofi, Cambridge, Massachusetts."}}}, {"fullName": "Struijs M", "firstName": "Martin", "lastName": "Struijs", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sanofi, Naarden, The Netherlands."}}}, {"fullName": "Bolwell B", "firstName": "Brian", "lastName": "Bolwell", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio."}}}, {"fullName": "DiPersio JF", "firstName": "John F", "lastName": "DiPersio", "initials": "JF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: jdipersi@wustl.edu."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "6", "volume": "24", "journalIssueId": "2694485", "dateOfPublication": "2018 Jun", "monthOfPublication": "6", "yearOfPublication": "2018", "printPublicationDate": "2018-06-01", "journal": {"title": "Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation", "ISOAbbreviation": "Biol Blood Marrow Transplant", "medlineAbbreviation": "Biol Blood Marrow Transplant", "NLMid": "9600628", "ISSN": "1083-8791", "ESSN": "1523-6536"}}, "pubYear": "2018", "pageInfo": "1187-1195", "abstractText": "The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n\u2009=\u2009167) and multiple myeloma (MM; n\u2009=\u2009163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240\u2009\u00b5g/kg plerixafor plus 10\u2009\u00b5g/kg G-CSF, or placebo plus 10\u2009\u00b5g/kg G-CSF to mobilize and collect CD34<sup>+</sup> cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.", "affiliation": "Division of Hematology, Mayo Clinic, Rochester, Minnesota.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "R35 CA210084", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P30 CA016520", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, Non-Hodgkin", "meshQualifierList": {"meshQualifier": {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Heterocyclic Compounds", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Granulocyte Colony-Stimulating Factor", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Mobilization", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Transplantation", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Transplantation, Autologous", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Survival Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Longitudinal Studies"}, {"majorTopic_YN": "N", "descriptorName": "Adolescent"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Child"}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}]}, "keywordList": {"keyword": ["Multiple myeloma", "Long-term follow-up", "Non-hodgkin Lymphoma", "Plerixafor", "Stem Cell Mobilization"]}, "chemicalList": {"chemical": [{"name": "Heterocyclic Compounds", "registryNumber": "0"}, {"name": "Granulocyte Colony-Stimulating Factor", "registryNumber": "143011-72-7"}, {"name": "plerixafor", "registryNumber": "S915P5499N"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.bbmt.2018.01.039"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6091693"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6091693?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.bbmt.2018.01.039"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "13", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS980871", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-04-01", "dateOfCreation": "2018-02-08", "firstIndexDate": "2018-02-08", "fullTextReceivedDate": "2020-10-26", "dateOfRevision": "2021-02-26", "electronicPublicationDate": "2018-02-02", "firstPublicationDate": "2018-02-02", "embargoDate": "2019-06-01"}, "abstract": "The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n\u2009=\u2009167) and multiple myeloma (MM; n\u2009=\u2009163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240\u2009\u00b5g/kg plerixafor plus 10\u2009\u00b5g/kg G-CSF, or placebo plus 10\u2009\u00b5g/kg G-CSF to mobilize and collect CD34<sup>+</sup> cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.", "Keywords": ["Multiple myeloma", "Long-term follow-up", "Non-hodgkin Lymphoma", "Plerixafor", "Stem Cell Mobilization"], "journaltitle": "Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation", "authorinfo": ["Micallef IN", "Stiff PJ", "Nademanee AP", "Maziarz RT", "Horwitz ME", "Stadtmauer EA", "Kaufman JL", "McCarty JM", "Vargo R", "Cheverton PD", "Struijs M", "Bolwell B", "DiPersio JF"], "title": "Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report."}